Discomfort after ureteral stenting in patients with urolithiasis. Calculus of kidney and ureter
Conditions
Interventions
Intervention 1: Control with placebo, a capsule similar to the tamsulosin capsule given to case group, contains inactive substance, administered once a day PO, for 14 days. Intervention 2: Tamsulosin,
Placebo
Treatment - Drugs
Control with placebo, a capsule similar to the tamsulosin capsule given to case group, contains inactive substance, administered once a day PO, for 14 days.
Tamsulosin, 0.4 mg capsule, oral administration, once a day for 14 days
Sponsors
Exir Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: age equal to 18 and more; urolithiasis indicated for transurethral litotripsy and Double J ureteral stenting thereafter. Exclusion criteria: significant ureteral trauma; presence of previous ureteral stent; other concurrent operations; previous prostate resection; bladder tumors; urinary infections; history of chronic pain; pregnancy; age less than 18; prostate cancer; cardiovascular disease, coronary artery disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain interference with sleep. Timepoint: day 14 of intervention. Method of measurement: questionnaire.;Pain interference with daily activity. Timepoint: day 14 of intervention. Method of measurement: questionnaire.;Frequency of urination. Timepoint: day 14 of intervention. Method of measurement: questionnaire.;Flank pain. Timepoint: day 14 of intervention. Method of measurement: questionnaire.;Severity of pain during urination. Timepoint: day 14 of intervention. Method of measurement: questionnaire.;Painkiller consumption. Timepoint: day 14 of intervention. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarshad Gholipour
Tehran University of Medical Sciences
Outcome results
None listed